Portola Pharmaceuticals Inc (NASDAQ:PTLA) Receives $26.67 Consensus Price Target from Brokerages

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have been assigned a consensus rating of “Hold” from the eleven ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $26.67.

A number of research firms have weighed in on PTLA. BidaskClub cut shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, June 18th. Morgan Stanley raised their price objective on shares of Portola Pharmaceuticals from $14.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Royal Bank of Canada started coverage on shares of Portola Pharmaceuticals in a report on Thursday, April 23rd. They set an “outperform” rating and a $20.00 price objective on the stock. Citigroup lowered shares of Portola Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Finally, Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday.

PTLA stock traded down $0.01 during midday trading on Friday, reaching $17.97. 1,778,476 shares of the company were exchanged, compared to its average volume of 2,041,714. The company has a debt-to-equity ratio of 4.77, a quick ratio of 4.82 and a current ratio of 4.87. Portola Pharmaceuticals has a 1-year low of $5.31 and a 1-year high of $31.73. The stock’s 50-day simple moving average is $17.89 and its 200 day simple moving average is $14.72. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -4.77 and a beta of 2.28.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). Portola Pharmaceuticals had a negative return on equity of 267.86% and a negative net margin of 232.73%. The company had revenue of $26.40 million for the quarter, compared to analyst estimates of $33.88 million. During the same period in the previous year, the business posted ($1.02) EPS. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year. On average, research analysts anticipate that Portola Pharmaceuticals will post -2.74 earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. Norges Bank purchased a new position in Portola Pharmaceuticals in the 4th quarter valued at $15,126,000. Bank of Montreal Can grew its position in Portola Pharmaceuticals by 31.8% in the 4th quarter. Bank of Montreal Can now owns 12,642 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 3,051 shares during the last quarter. Geode Capital Management LLC grew its position in Portola Pharmaceuticals by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,022,267 shares of the biopharmaceutical company’s stock valued at $24,411,000 after buying an additional 77,159 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Portola Pharmaceuticals in the 4th quarter valued at $3,898,000. Finally, Blair William & Co. IL boosted its position in shares of Portola Pharmaceuticals by 7.7% during the 4th quarter. Blair William & Co. IL now owns 164,449 shares of the biopharmaceutical company’s stock worth $3,927,000 after purchasing an additional 11,795 shares in the last quarter. Hedge funds and other institutional investors own 98.68% of the company’s stock.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Featured Article: Accumulation/Distribution

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.